Sickle Cell DiseasePipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Sickle-cell diseasesÂ (SCD) are types of blood disordersÂ which are usuallyÂ inherited genetically.Â One of the common types of SCDs is theÂ sickle-cell anemiaÂ or SCA. It essentially gives rise to an irregularity in hemoglobin, the proteinÂ that carries oxygen in the blood. Hemoglobin is found typically inÂ the red blood cells of the body. As a result, a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis,Â swelling in the limbs,Â microbial infections, and in certain cases, stroke.Â SCD is diagnosed by blood tests and Hb electrophoresis. Hydroxyurea is the only FDA approved drug for treatment of Sickle-cell diseases.
By Trial Phase, Sickle Cell Diseasepipeline drugs are segmented as:
By Company, Sickle Cell Diseasepipeline drugs are segmented as:
By Drugs, Sickle Cell Disease pipeline drugs are segmented as:
By Type of Disease, Sickle Cell Disease pipeline drugs are segmented as:
By Route of Administration, Sickle Cell Diseasepipeline drugs are segmented as:
Sickle Cell DiseaseDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sickle Cell Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sickle Cell Diseasedisease pipeline drugs development. This report studies the dynamics of the Sickle Cell DiseaseDisease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sickle Cell Diseasedisease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.